Press Release: EMA releases guidance on the use of pharmacogenomics to improve safety monitoring of medicines

The European Medicines Agency released in January 2014 a draft guideline for public consultation which addresses how pharmacogenomics can support pharmacovigilance activities and in particular how the results of pharmacogenomic studies can help optimise the use of medicines.

Pharmacogenomics is the study of how the genetic makeup of a person affects his or her response to certain medicines, both in terms of efficacy and safety. It is an important new tool that can optimise the use of medicines, by helping to target patients who are likely to respond better to the treatments and helping to mitigate and manage their risks more efficiently.

• Primary Source

EMA: Guideline, 30.01.14: Draft guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500160232&murl=menus/document_library/document_library.jsp&mid=0b01ac058009a3dc

---